NEW YORK, June 14 /PRNewswire-FirstCall/ -- Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB: XE7), the source of next-generation medical DNA diagnostic technologies, announced today initiation of patient enrollment in Europe for its clinical development program of a tuberculosis test using its proprietary Transrenal DNA (Tr-DNA)-based technology.
